EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis

Kevin D Deane iD, Christopher C Striebich, Marie L Feser, James R O'Dell, Judith A James iD, Jeffrey A Sparks iD, John M Davis iD, Jonathan Graf, Maureen A McMahon iD, Elizabeth B Solow, Lindsy J Forbess, Athan Tiliakos und 22 weitere

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.43366 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Kevin D Deane und 33 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado Anschutz, Aurora, Colorado. Hauptthemen laut MEDLINE: Hydroxychloroquine, Arthritis, Rheumatoid, Antirheumatic Agents, Anti-Citrullinated Protein Antibodies. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Individuals with serum elevations of anti–cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such at‐risk individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.

Methods

In this phase 2 randomized trial, individuals at risk for RA with anti‐CCP3 ≥2 times the upper limit of normal (ULN) were assigned to receive HCQ or placebo for 12 months, with up to 24 months of postdrug follow‐up. The primary outcome was the development of clinical RA, as defined in the protocol, at 36 months. Secondary outcomes included safety, development of inflammatory arthritis (IA), and participant‐reported joint symptoms.

Results

Of 144 randomized participants, 71 were assigned to HCQ and 73 to placebo. In the modified intent‐to‐treat population, clinical RA occurred in 21 of 69 (30.4%) participants in the HCQ group and 24 of 73 (32.9%) in the placebo group. The risk of clinical RA at 36 months was 0.336 with HCQ and 0.394 with placebo (difference −0.058; 95% confidence interval −0.336 to 0.220; P = 0.52). Results for IA were similar. The occurrence and severity of joint symptoms were not observed to differ between groups. Adverse event incidence was similar between groups.

Conclusion

In this trial involving individuals with anti‐CCP3 levels ≥2 times the ULN, 12 months of HCQ did not prevent the development of clinical RA at 36 months. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxychloroquineArthritis, RheumatoidAntirheumatic AgentsAnti-Citrullinated Protein AntibodiesHumansFemaleMaleMiddle AgedAdultAgedDouble-Blind MethodPeptides, Cyclic

Substanzen

HydroxychloroquineAntirheumatic AgentsAnti-Citrullinated Protein AntibodiesPeptides, Cyclic

Autor:innen und Institutionen

  • University of Colorado Anschutz, Aurora, Colorado.
  • University of Nebraska Medical Center, Omaha, Nebraska.
  • Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mayo Clinic Rochester, Rochester, Minnesota.
  • University of California, San Francisco School of Medicine, San Francisco, California.

ORCID-Profile: Kevin D Deane, Judith A James, Jeffrey A Sparks, John M Davis, Maureen A McMahon, Jonathan Kay, Janel Fedler, V Michael Holers

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Deane, K. D., Striebich, C. C., Feser, M. L., O'Dell, J. R., James, J. A., Sparks, J. A., Davis, J. M., Graf, J., McMahon, M. A., Solow, E. B., Forbess, L. J., Tiliakos, A., Schiopu, E., Danila, M. I., Horowitz, D. L., Kay, J., Strickland, C. D., Guthridge, J. M., Arriens, C., …, & Holers, V. M. (2026). A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.43366

Vancouver

Deane KD, Striebich CC, Feser ML, O'Dell JR, James JA, Sparks JA, et al. A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis. Arthritis & Rheumatology. 2026. doi:10.1002/art.43366

BibTeX
@article{Deane2026,
  author = {Deane, Kevin D and Striebich, Christopher C and Feser, Marie L and O'Dell, James R and James, Judith A and Sparks, Jeffrey A and Davis, John M and Graf, Jonathan and McMahon, Maureen A and Solow, Elizabeth B and Forbess, Lindsy J and Tiliakos, Athan and Schiopu, Elena and Danila, Maria I and Horowitz, Diane L and Kay, Jonathan and Strickland, Colin D and Guthridge, Joel M and Arriens, Cristina and Grossman, Jennifer M and Kristen Demoruelle, M and Bemis, Elizabeth A and Frazer-Abel, Ashley and Fleischer, Chelsie L and Fox, David A and Mikuls, Ted R and Greenleaf, Melissa and York, Kate and Walker, Sarah and Keyes-Elstein, Lynette and Byron, Margie and Fedler, Janel and Goldmuntz, Ellen A and Holers, V Michael},
  title = {A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.43366}
}
Kostenlos starten →